Document is current

Any future updates will be listed below

Lenacapavir, a first-in-class, long-acting capsid inhibitor approved for both HIV-1 treatment and prevention

Crossref DOI link: https://doi.org/10.1007/s00044-025-03495-1

Published Online: 2025-10-31

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark